Lecanemab, aducanumab, and donanemab bind the same human Alzheimer disease Aβ aggregates at different epitopes
Within the limitations of measuring in vitro equilibrium binding activity of in-house recombinant antibodies to aqueously extracted Aβ from human postmortem brain tissue, we could not discern a population of Aβ aggregates (e.g. protofibrils) accessible to one antibody but not the other two. Antibody preference for CAA Aβ over plaque Aβ does not explain differences in clinical trial ARIA rates.
Authors
- Michael B. Miller (ORCID: https://orcid.org/0000-0002-6205-3314)
- Angela L. Meunier
- Amirah K. Anderson (ORCID: https://orcid.org/0009-0002-5612-3838)
- Cynthia A. Lemere (ORCID: https://orcid.org/0000-0002-2983-7870)
- Anna Francis
- Elizabeth L. Hennessey
- Andrew M Stern
- Dennis J. Selkoe
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70855_099914
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00